Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.
| Drug | Target | Relationship | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | Reposition | #cancers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin | PRKAA1 | Direct | 1 | ||||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | RET | SSL via RET | 4 | ||||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | RET | SSL via RET | 4 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | PIK3CG | SSL via PIK3CG | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | RET | SSL via RET | 3 | ||||||||
| pembrolizumab, belzutifan, lenvatinib | RET | SSL via RET | 3 | ||||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | RET | SSL via RET | 2 | ||||||||
| cabozantinib | RET | SSL via RET | 2 | ||||||||
| cabozantinib, atezolizumab, cabozantinib, cabozantinib | RET | SSL via RET | 2 | ||||||||
| entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib | RET | SSL via RET | 2 | ||||||||
| gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a | RET | SSL via RET | 2 | ||||||||
| lenvatinib, pembrolizumab | RET | SSL via RET | 2 | ||||||||
| lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate | RET | SSL via RET | 2 | ||||||||
| mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a | RET | SSL via RET | 2 | ||||||||
| pembrolizumab, lenvatinib | RET | SSL via RET | 2 | ||||||||
| pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu | RET | SSL via RET | 2 | ||||||||
| pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin | RET | SSL via RET | 2 | ||||||||
| quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery | RET | SSL via RET | 2 | ||||||||
| regorafenib | RET | SSL via RET | yes | 2 | |||||||
| regorafenib, laboratory biomarker analysis | RET | SSL via RET | 2 | ||||||||
| sorafenib, administered orally, ct/mri | RET | SSL via RET | 2 | ||||||||
| adjuvant therapy, temozolomide, valproic acid, radiation therapy | CDKN1A | SSL via CDKN1A | 1 | ||||||||
| adriamycin, cyclophosphamide, vindesine, valproic acid | CDKN1A | SSL via CDKN1A | 1 | ||||||||
| alisertib | AURKA | SSL via AURKA | 1 | ||||||||
| alisertib, gemcitabine | AURKA | SSL via AURKA | 1 | ||||||||
| arsenic trioxide | CDKN1A | SSL via CDKN1A | 1 | ||||||||
| arsenic trioxide, radiation therapy | CDKN1A | SSL via CDKN1A | 1 | ||||||||
| arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy | CDKN1A | SSL via CDKN1A | 1 | ||||||||
| atezolizumab, cabozantinib | RET | SSL via RET | 1 | ||||||||
| atorvastatin, temozolomide, radiotherapy | HMGCR | SSL via HMGCR | 1 | ||||||||
| biopsy, biospecimen collection, ceralasertib, computed tomography, echocardiography, multigated acquisition scan, positron emission tomography, trastuzumab deruxtecan | ATR | SSL via ATR | 1 | ||||||||
| biopsy, biospecimen collection, computed tomography, copanlisib, magnetic resonance imaging | PIK3CG | SSL via PIK3CG | 1 | ||||||||
| biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging | RET | SSL via RET | 1 | ||||||||
| biopsy, biospecimen collection, copanlisib, radiologic examination | PIK3CG | SSL via PIK3CG | 1 | ||||||||
| biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography | RET | SSL via RET | 1 | ||||||||
| bosutinib | CAMK2G | SSL via CAMK2G | 1 | ||||||||
| cabozantinib, durvalumab, tremelimumab | RET | SSL via RET | 1 | ||||||||
| cabozantinib, nivolumab | RET | SSL via RET | 1 | ||||||||
| cabozantinib, pembrolizumab | RET | SSL via RET | 1 | ||||||||
| ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin | TP53 | SSL via TP53 | 1 | ||||||||
| ceralasertib, olaparib, durvalumab | ATR | SSL via ATR | 1 | ||||||||
| cisplatin, carboplatin, etoposide, durvalumab, ceralasertib | ATR | SSL via ATR | 1 | ||||||||
| cisplatin, pemetrexed disodium, sorafenib | RET | SSL via RET | 1 | ||||||||
| enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) | AURKA | SSL via AURKA | 1 | ||||||||
| enzastaurin, lomustine | AURKA | SSL via AURKA | 1 | ||||||||
| enzastaurin, temozolomide, radiation therapy | AURKA | SSL via AURKA | 1 | ||||||||
| erdafitinib | RET | SSL via RET | 1 | ||||||||
| everolimus, sorafenib | RET | SSL via RET | 1 | ||||||||
| gemcitabine, erlotinib, sorafenib | RET | SSL via RET | 1 | ||||||||
| gemcitabine, oxaliplatin, imatinib | RET | SSL via RET | 1 | ||||||||
| gemcitabine, placebo, sorafenib | RET | SSL via RET | 1 | ||||||||
| gemcitabine, sorafenib, radiotherapy | RET | SSL via RET | 1 | ||||||||
| gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff | RET | SSL via RET | 1 | ||||||||
| h101, tislelizumab, lenvatinib | RET | SSL via RET | 1 | ||||||||
| hyperfractionated radiation therapy, stereotactic radiosurgery, alisertib, quality-of-life assessment | AURKA | SSL via AURKA | 1 | ||||||||
| imatinib, irinotecan, carboplatin | RET | SSL via RET | 1 | ||||||||
| inotuzumab ozogamicin, flag (fludarabine, cytarabine and g-csf), hidac (high dose cytarabine), cytarabine and mitoxantrone | CD22 | SSL via CD22 | 1 | ||||||||
| irinotecan, cisplatin, simvastatin | HMGCR | SSL via HMGCR | 1 | ||||||||
| ko-2806, cabozantinib, adagrasib | RET | SSL via RET | 1 | ||||||||
| lenalidomide, bevacizumab, sorafenib, temsirolimus, lenalidomide, oxaliplatin, leucovorin, 5-fluorouracil | RET | SSL via RET | 1 | ||||||||
| lenvatinib, bevacizumab | RET | SSL via RET | 1 | ||||||||
| medical cannabis | HMGCR | SSL via HMGCR | 1 | ||||||||
| nabiximols, temozolomide, nabiximols-matched placebo | HMGCR | SSL via HMGCR | 1 | ||||||||
| nivolumab, cabozantinib | RET | SSL via RET | 1 | ||||||||
| oxaliplatin, sorafenib | RET | SSL via RET | 1 | ||||||||
| paclitaxel, irinotecan, pembrolizumab, mk-4830, lenvatinib, sacituzumab tirumotecan, antihistamine, h2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) | RET | SSL via RET | 1 | ||||||||
| pembrolizumab, coformulation favezelimab/pembrolizumab, mk-4830, lenvatinib, irinotecan, paclitaxel | RET | SSL via RET | 1 | ||||||||
| pembrolizumab, lenvatinib, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, paclitaxel | RET | SSL via RET | 1 | ||||||||
| ponatinib | RET | SSL via RET | 1 | ||||||||
| radiation therapy, temozolomide, sorafenib | RET | SSL via RET | 1 | ||||||||
| regorafenib, lomustine | RET | SSL via RET | 1 | ||||||||
| regorafenib, nivolumab, capeox, folfox regimen | RET | SSL via RET | 1 | ||||||||
| regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil | RET | SSL via RET | 1 | ||||||||
| regorafenib, temozolomide | RET | SSL via RET | 1 | ||||||||
| rosuvastatin | HMGCR | SSL via HMGCR | yes | 1 | |||||||
| selpercatinib | RET | SSL via RET | yes | 1 | |||||||
| serplulimab, lenvatinib, paclitaxel/paclitaxel-albumin/paclitaxel liposome | RET | SSL via RET | 1 | ||||||||
| sirolimus, vandetanib | RET | SSL via RET | 1 | ||||||||
| sorafenib | RET | SSL via RET | yes | 1 | |||||||
| sorafenib tosylate, valproic acid, sildenafil citrate | CDKN1A | SSL via CDKN1A | 1 | ||||||||
| sorafenib, erlotinb | RET | SSL via RET | 1 | ||||||||
| sorafenib, rad001 | RET | SSL via RET | 1 | ||||||||
| sorafenib, radiofrequency ablation (rfa) or surgery, everolimus, lanreotide | RET | SSL via RET | 1 | ||||||||
| tace, lenvatinib, combined with tislelizumab group | RET | SSL via RET | 1 | ||||||||
| tace, tislelizumab, lenvatinib | RET | SSL via RET | 1 | ||||||||
| temozolomide, lomustine, regorafenib, radiation, paxalisib, val-083, vt1021, troriluzole, adi-peg 20 | RET | SSL via RET | 1 | ||||||||
| topotecan, sorafenib | RET | SSL via RET | 1 | ||||||||
| trc 105, sorafenib | RET | SSL via RET | 1 | ||||||||
| valproic acid | CDKN1A | SSL via CDKN1A | 1 | ||||||||
| valproic acid, bevacizumab, radiation therapy | CDKN1A | SSL via CDKN1A | 1 | ||||||||
| valproic acid, simvastatin 20mg, gemcitabine 1000 mg, nab paclitaxel, cisplatin, capecitabine | CDKN1A | SSL via CDKN1A | 1 | ||||||||
| vandetanib | RET | SSL via RET | yes | 1 | |||||||
| vandetanib, 5 fluorouracil (fu), carboplatin, paclitaxel, external beam radiation therapy (rt) | RET | SSL via RET | 1 | ||||||||
| vandetanib, adjuvant therapy | RET | SSL via RET | 1 | ||||||||
| vemurafenib, sorafenib | RET | SSL via RET | 1 | ||||||||
| alectinib | RET | SSL via RET | yes | 0 | |||||||
| alectinib hydrochloride | RET | SSL via RET | yes | 0 | |||||||
| atorvastatin | HMGCR | SSL via HMGCR | yes | 0 | |||||||
| atorvastatin calcium | HMGCR | SSL via HMGCR | yes | 0 | |||||||
| cerivastatin | HMGCR | SSL via HMGCR | yes | 0 |